Idotrim (Trimethoprim)

Idotrim is an antibacterial agent used to manage infections of the urinary tract and related conditions.

• Uncomplicated urinary tract infection: eradicates common uropathogens causing the infection.
• Acute cystitis: relieves infection symptoms and promotes bacterial clearance.
• Prophylaxis of recurrent urinary tract infections: reduces the frequency of future episodes.

• Trimethoprim inhibits bacterial dihydrofolate reductase, an enzyme essential for folic acid synthesis. By blocking this pathway, the drug prevents the production of nucleic acids required for bacterial replication, leading to a bacteriostatic effect against susceptible organisms.

Adverse reactions may occur with trimethoprim therapy.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Vomiting: occasional episodes.
• Loss of appetite: reduced desire to eat.
• Rash: mild skin irritation.
• Headache: transient mild headache.
• Diarrhea: loose stools.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Stevens‑Johnson syndrome: rare severe skin disorder.
• Blood dyscrasias: agranulocytosis, aplastic anemia, or severe leukopenia.
• Kidney toxicity: impaired renal function.
• Liver enzyme elevation: signs of hepatic stress.

Use trimethoprim with caution in specific clinical situations.

• Renal impairment: monitor kidney function and adjust therapy as needed.
• Hepatic disease: use carefully; monitor liver enzymes.
• Pregnancy: safety not established; avoid unless clearly indicated.
• Concurrent folate antagonists: increased risk of bone‑marrow suppression.
• Known hypersensitivity: discontinue immediately if allergic reaction occurs.
• Store at ambient temperature: keep in original packaging, protect from moisture.

Trimethoprim may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Methotrexate: increased toxicity and risk of bone‑marrow suppression.
• Phenytoin: reduced efficacy of trimethoprim, possible therapeutic failure.
• Sulfonamides: additive folate antagonism leading to heightened toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, increasing bleeding risk.
• ACE inhibitors: potential for hyperkalemia, especially in renal impairment.
• Diuretics: may increase risk of renal dysfunction when combined.